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Despite intense research efforts, the knowledge about the mechanisms of epileptogenesis and epilepsy is still
considered incomplete and limited. However, an in-depth understanding of molecular pathophysiological pro-
cesses is crucial for the rational selection of innovative biomarkers and target candidates.
Here, we subjected proteomic data from different phases of a chronic rat epileptogenesis model to a comprehen-
sive systems level analysis. Weighted Gene Co-expression Network analysis identiﬁed several modules of inter-
connected protein groups reﬂecting distinct molecular aspects of epileptogenesis in the hippocampus and the
parahippocampal cortex. Characterization of these modules did not only further validate the data but also re-
vealed regulation of molecular processes not described previously in the context of epilepsy development. The
data sets also provide valuable information about temporal patterns, which should be taken into account for de-
velopment of preventive strategies in particular when it comes to multi-targeting network pharmacology
approaches.
In addition, principal component analysis suggests candidate biomarkers,whichmight inform thedesign of novel
molecular imaging approaches aiming to predict epileptogenesis during different phases or conﬁrm epilepsy
manifestation. Further studies are necessary to distinguish between molecular alterations, which correlate
with epileptogenesis versus those reﬂecting a mere consequence of the status epilepticus.











Epilepsy is among the most common neurological disorders requir-
ing chronic therapeutic management. Thirty percent of all patients do
not respond to available anti-epileptic drugs (AEDs) (Potschka and
Brodie, 2012) with a particular high rate of drug resistance in patients
with acquired epilepsies. Limitations in epilepsy treatment spur a grow-
ing interest in the development of preventive approaches, which can be
applied in patients who experienced an epileptogenic brain insult
(Kobowet al., 2012). Thedesign and validation of respective approaches
faces several challenges. The complexity of the molecular and cellular
alterations characterizing epileptogenesis following an initial brain in-
sult renders it difﬁcult to pick the most promising targets for anti-epi-
leptogenic concepts in a straightforward manner. The uncertainty in
the timing of epileptogenesis requires elaborate and time-consuming
preclinical and clinical research (White, 2012; Schmidt, 2012). Post-in-
sult epilepsy can developwith a latency period ofmonths, years, or even
decades (Schmidt, 2012; Trinka and Brigo, 2014). Biomarkers that allow
for early conclusions about the success of an intervention and limit the
necessary duration of a clinical trial are urgently needed. Brain insults
only pose patient subgroups at risk for epilepsy development with the
individual outcome depending on various factors including genetic
and physiological factors as well as, the disease history. Stratiﬁcation
of patients with a comparable brain insult by an actual risk of
epileptogenesis is highly desirable. For these purposes the availability
of valid epileptogenesis biomarkers, which for instance render a basis
for respective molecular imaging approaches, is essential. Moreover,
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an in-depth understanding of the sequence of pathophysiological
events is a prerequisite for the rationale selection of target candidates
and the respective time window for intervention.
Animalmodels of epileptogenesis can provide information about the
regulation patterns of functional groups of proteins. Bioinformatic ap-
proaches to analyze genomic, transcriptomic and proteomic data can in-
tegrate the complex data from such omics studies with the vast amount
of information collected and curated in biological databases. Findings
obtained can guide the selection of novel target and biomarker
candidates.
Knowledge-based proteomics analysis can provide comprehensive
information about disease-associated alterations in molecular patterns
at the functionally relevant level and might guide the identiﬁcation of
key proteins in the pathogenesis of epilepsy. Therefore, we collected in-
dividual hippocampal and parahippocampal cortex samples in a rat
model at three different time points during epileptogenesis and
analysed the proteome alterations using an LC/MS-MS approach. Here,
we completed a broader analysis of the data set previously subjected
to an analysis focused on proteins speciﬁcally linkedwith inﬂammation
and immune response (Walker et al., 2016). We applied a Weighted
Gene Co-expression Network Analysis (WGCNA) approach
(Langfelder and Horvath, 2008) to unveil a network of
epileptogenesis-associated protein modules and to identify
intramodular hub proteins. WGCNA has been successfully applied to
discover hub gene association in many conditions including atrial ﬁbril-
lation (Tan et al., 2013), Alzheimer's disease (Miller et al., 2010),
Huntington's disease (Shirasaki et al., 2012), autism spectrum disorder
(Huang et al., 2016), and schizophrenia (Ren et al., 2015; de Jong et
al., 2012). The ﬁndings can guide future selection of promising target
candidates and their rational combination in multi-targeting
approaches.
To identify proteins that distinguish between groups and might
serve as biomarker candidates, we have subjected the protein data
sets collected during the early post-insult phase, the latency phase,
and the chronic epilepsy phase to principal component analysis. The re-
sults suggest several novel proteins that are prominently regulated dur-
ing epileptogenesis, and that might serve as potential target and
biomarker candidates. Processed data are available as supplementary
ﬁle, Cytoscape network ﬁles and R scripts are available as hosted at
http://doi.org/10.5281/zenodo.438918.
2. Materials and methods
2.1. Animals
The animal experiment of this study has been carried out in accor-
dance with the German Animal Welfare act and the EU directive
2010/63/EU as approved by the responsible government (reference
number 55.2-1-54-2532-94-11). Female Sprague Dawley rats (n =
59; 200–224 g) were used in the experiment and were housed under
controlled standard environmental conditions (20–24 °C, 45–65% hu-
midity, light cycle from 7:00 a.m.–7:00 p.m.). Please note that female
rats were used based on our characterization of the model (Brandt et
al., 2003), which revealed a high mortality rate in male rats.
The ratswere purchased fromHarlan Laboratories (Udine, Italy) and
were allowed to habituate to the new environmental conditions for at
least oneweek. During the experiment every attemptwasmade tomin-
imize the number of animals used in the study and to avoid any pain or
discomfort.
2.2. Post-status epilepticus model
Stereotactical implantation of the combined recording and stimula-
tion electrode into the right anterior basolateral amygdala was per-
formed as previously described by Walker et al. (2016). With a time
interval of at least six weeks post-surgery a status epilepticus (SE) was
induced as described by Ongerth et al. (2014). Two days, ten days and
eight weeks post SE, the rats were sacriﬁced and brain tissue of the hip-
pocampus (HC) and parahippocampal cortex (PHC) was used for mass
spectrometry. Animals from the eightweeks groupunderwent a contin-
uous video- and EEG-monitoring (24 h per day/7 days a week over
19 days) using a combined EEG- and video-detection system as previ-
ously described by Pekcec et al. (2008). Only animals with at least one
spontaneous generalized seizure were used for further analysis.
2.3. Mass spectrometry, label-free quantiﬁcation and protein identiﬁcation
Control (n= 5) and SE (n= 5) animals were euthanized with pen-
tobarbital (500 mg/kg i.p.; Narcoren®, Sigma-Aldrich GmbH, Munich,
Germany). Tissue preparation and LC-MS/MS analysis were performed
as described previously (Walker et al., 2016). For label-free quantiﬁca-
tion and protein identiﬁcation the acquired MS spectra were loaded
into the Progenesis LC-MS software (Version 2.5, Nonlinear Dynamics)
and label-free quantiﬁcation was analysed as described by Hauck et al.
(2010, 2012) and Walker et al. (2016). Brieﬂy, only unique peptides of
an identiﬁed protein were used for quantiﬁcation. To measure the
total cumulative normalized abundance all peptides assigned to the re-
spective protein were summarized. Only proteins quantiﬁed with at
least two peptides were included for further analysis.
2.4. Pre-processing of data
Following LC-MS/MS, the corresponding gene symbols for all quan-
tiﬁed proteins were taken from the Ensembl database (http://www.
ensembl.org/Rattus_norvegicus/; version 69; 32,971 sequences). In
case a gene symbol had not been established in the rat genome annota-
tion, the human orthologue was used. Proteins with missing values
were excluded from further analysis. Expression values of each time
pointwere arcsine-transformed,median centered and analysed by prin-
cipal component analysis (PCA) implemented in R software packages
“FactoMineR” (Lê et al., 2008) and “factoextra” (Kassambara, 2015).
To explain variation between protein proﬁles of SE and control groups,
the top 10 contributing proteins at the ﬁrst PCA dimensionwere further
analysed.
Differentially expressed proteins were deﬁned as proteins with fold
change ≥1.5 (up-regulated in SE samples) or fold change ≤0.67 (down-
regulated in SE samples) and p-values b 0.05, estimated by empirical
Bayes method in “limma” R package (Smyth, 2004).
2.5. Protein co-expression network construction and module detection
To study the correlation of protein expression proﬁles between dif-
ferent time points, further analysis comprised proteins identiﬁed at all
three time points. Some identiﬁed proteins mapped to the same gene
symbol; we selected the ones that had the highest number of unique
peptides, which were used for quantiﬁcation. Protein co-expression
networks were constructed with the R package WGCNA (Weighted
Gene Co-expression Network Analysis) (Langfelder and Horvath,
2008). We calculated Spearman correlation coefﬁcient between nor-
malized protein expression proﬁles and converted the correlation ma-
trix into a weighted adjacency matrix with a soft threshold β = 6.
Topological analysis by density, centralization, heterogeneity, mean
clustering coefﬁcient and mean scaled connectivity were retrieved by
the function fundamentalNetworkConcepts of WGCNA and modules
were identiﬁed by topological overlap dissimilarity measure. Topologi-
cal overlap indicates the relative interconnectedness between twomol-
ecules, thus identiﬁcation of modules from topological dissimilarity
results in membership of proteins that have a similar expression pat-
tern. Dynamic tree cut of the network dendrogram was performed
with parameters minClusterSize= 20 and deepSplit= 2.
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2.6. Hub proteins and module signiﬁcance
The proteins with highest connectivity within the module were de-
ﬁned as intramodular hubs. Since the biological plausibility and clinical
utility of hubs varies, functional enrichment of the module can further
help to prioritize the hub proteins for validation. Functional enrichment
was determined by Core Analysis in Ingenuity Pathways Analysis (IPA;
(Racine et al., 2011)). Disease association of the hub proteins was per-
formed in DisGeNET (Pinero et al., 2015) and IPA. DisGeNET scores rep-
resent the level of evidence for gene-disease association, based on the
number and type of sources (level of curation, model organisms) and
the number of publications supporting the association.
The network was exported for visualization in Cytoscape (Shannon
et al., 2003), where module membership was denoted as an attribute.
Module expression proﬁles were summarized in module eigengenes.
We calculated Spearman correlation between the module eigengenes
and phenotype (SE and control animals) at each time point. Student as-
ymptotic p-values below 0.001 in at least two time points indicated sig-
niﬁcant module-phenotype relationship.
2.7. Code availability
All R packages used for MS data processing and network construc-
tion are publicly available. Data analysis codes that produce the present-
ed results and ﬁgures were written in R (v 3.2.1) and together with
Cytoscape network ﬁles can be accessed at http://doi.org/10.5281/
zenodo.438918.
2.8. Immunohistochemistry
Immunohistochemistry was performed for three selected proteins
to conﬁrm the result of mass spectrometry analysis. For this purpose,
animals were euthanized with an intraperitoneal injection of pentobar-
bital (500mg/kg; Narcoren®, Sigma-AldrichGmbH,Munich, Germany).
Next, animals were decapitated, the brains were removed and stored in
4% paraformaldehyde in 0.1 M phosphate-buffered saline (pH 7.4) at 4
°C for three days. Serial blocks were embedded in parafﬁn by using an
embeddingworkstation (Histomaster 2050/Di, Bavimed, Birkenau, Ger-
many). Coronal sections (2 μm) were cut on a microtome (1165/
Rotocut, Reichert-Jung, Nußloch, Germany) from these blocks and rep-
resentative regions were selected for immunohistochemistry. For the
PHC stainings (annexin A3, eukaryotic translation initiation factor 3
subunit C) we used sections close to bregma = −4.80, while for HC
staining (clusterin) we used bregma =−5.40 according to the rat ste-
reotaxic atlas (Paxinos and Watson, 2007) For all tissues we used the
whole mount staining technique. Brieﬂy, sections were initially
deparafﬁnized with ethanol scale, processed for heat-induced epitope
retrieval (HIER) with sodium citrate buffer (pH 6.0) in microwave
oven at 720 W for 20 min. Samples were then washed in 0.01 M PBS
at room temperature and endogenous peroxidase was inhibited for
30 min in 3% H2O2 in 0.01 M PBS. Tissue underwent a blocking step of
1 h in 0.01 M PBS containing 0.3% Tween-20, 2% bovine serum albumin
and 5% normal donkey serum. Brain slices were then incubated over-
night (16 h) with primary antibodies: i) rabbit polyclonal Anti-ANXA3
(Sigma-Aldrich Cat# HPA013398 RRID: AB_1844861) at 1:1000 dilu-
tion, ii) rabbit polyclonal Anti-Apolipoprotein J Polyclonal (Bioss Inc.
Cat# bs-1354R RRID: AB_10856803) at 1:100 dilution, iii) Anti- EIF3C
antibody (Biorbyt Cat# orb247746) at 1:500 dilution. The following
day, after three washes in 0.01 M PBS, sections were incubated for 2 h
at room temperature with biotinylated donkey anti-rabbit IgG (Jackson
ImmunoResearch Labs Cat# 711-065-152 RRID:AB_2340593). Sections
were then rinsed thrice in 0.01M PBS and then incubated at room tem-
perature for 1 hwith VECTASTAINABC-Peroxidase Kit (Vector Laborato-
ries Cat# PK-4000 RRID:AB_2336818) and stained using the avidin–
biotin complex indirect technique (Gualtieri et al., 2012) with diamino-
benzidine tablets (Sigma Aldrich, D4293 SIGMAFAST 3,3′-
Diaminobenzidine tablets) as chromogen. Brain samples were then
rinsed in water, dried and coverslipped with mounting medium
(Millipore - 107960 Entellan) for image analysis.
2.9. Image analysis
For each animal, images for the HC or PHC were captured at 10×
magniﬁcation by an Olympus BH-2 microscope connected to a video
camera (Zeiss AxioCamMRc, Germany) and post processed for analysis
with ImageJ software (NIH, USA) andAdobe Photoshop CS6 (Adobe Sys-
tems, USA). The person performing the quantiﬁcation was unaware of
the group allocation of the samples.
Images were processed for area measurement and were initially
converted in 8bit type; the region of interest (ROI) for each staining
was outlined. For annexin A3 we analysed the piriform cortex, for clus-
terin the dorsal and the ventral HC, for eukaryotic translation initiation
factor 3 subunit C the amygdalopiriform transition. The threshold func-
tionwas then applied to the ROI and the triangle ﬁlter (Zack et al., 1977)
was chosen since this implementation uses robust (default is 1% and
99%) estimation of image histogram ends. For every image, thresholded
and total ROI areas were obtained and the amount of thresholded ROI
areas was normalized on the investigated area as follows:
Protein marker normalizedð Þ ¼ thresholded area=ROI area
Values obtained for each experimental group were compared be-
tween SE animals and control animals for each protein marker.
2.10. Statistical analysis
Immunhistochemistry data were analysed using Prism 5.0
(Graphpad Software, USA). Statistical analysis was performed with t-
test. All values are expressed as mean ± SEM. For all analyses p b 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Data preprocessing
A total of 2653 proteins were detected in at least one time point by
LTQ OrbitrapXL, 2241 in the HC samples and 2394 in the PHC.
In the HC, 1337 proteins were identiﬁed at all three time points and
1371 in the PHC. The overlap between the two brain regions comprises
2125 proteins and 1125 proteins after ﬁltering by presence at all time
points. After normalization, GLI pathogenesis-related 2 (Glipr2) in HC
data was identiﬁed as an outlier and removed from further analysis.
Correlation between samples shows a clear separation of the third
time point (Supplementary Fig. 1). Differential expression analysis of
HC data indicated 121 proteins differentially expressed at two days,
276 proteins at ten days and 14 proteins at eight weeks post SE
(Fig. 1a, Supplementary Fig. 2a). In the PHC 218, 419, and 223 proteins
proved to be differentially expressed two days, ten days, and eight
weeks post SE, respectively (Fig. 1b, Supplementary Fig. 2b). Differen-
tially expressed proteins of all three time points exhibited an overlap
of 4 proteins in the HC (Fig. 1c) and 23 proteins in the PHC (Fig. 1d).
The overlap between proteins dysregulated during the early post-insult
phase and the latency phase comprised 43 and 129 proteins in the HC
and PHC, respectively. Three and 41 proteins exhibited a regulation dur-
ing the latency phase, which extended into the chronic phase.
Comparison between brain regions revealed an overlap of 27 pro-
teins two days post SE (Fig. 1e), 87 proteins ten days post SE (Fig. 1f)
and 8 proteins eight weeks post SE (Fig. 1g) co-regulated in the HC
and PHC.
The functional annotation of differentially expressed proteins re-
vealed a typical pattern for many protein groups linkedwith speciﬁc bi-
ological processes (Fig. 2a (HC) and b (PHC)) and molecular function
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(Fig. 2c (HC) and d (PHC)) exhibiting an early dysregulation, a more
pronounced regulation during the latency phase, and a reduction in
the number of regulated proteins in the chronic phase. Interestingly,
the same functional groups showed the most intense regulation in the
HC and PHC. Regarding biological processes these included proteins as-
sociated with cellular component organization and biogenesis, cellular
processes, localization and metabolic processes. Among the groups
linked with a particular molecular function, proteins associated with
binding, structural molecule activity, and catalytic activity stood out
with prominent regulation.
3.2. HC and PHC networks and modules
Weighted co-expression networks were constructed from all pro-
teins identiﬁed at three time points in the HC and PHC. The constructed
networks had a similar topology in terms of density, heterogeneity, and
Fig. 1.Differentially expressed proteins: Differentially expressed proteins of the HC and the PHC are shown in (a and b). A positive sign (+) indicates up-regulated expression, whereas a
negative sign (−) displays down-regulated expression of proteins in SE animals compared to control animals. The overlap between differentially expressed proteins of all time points is
illustrated by Venn diagrams for the HC (c) and the PHC (d). (e–g) show the overlap between the two tissues (HC and PHC) two days (e), ten days (f) and eight weeks (g) post SE.
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clustering coefﬁcient (Supplementary Table 1). Both HC and PHC net-
works have a free-scale topology and strong connectivity. Hierarchical
clustering of protein expression proﬁles identiﬁed groups of co-
expressed proteins (modules). Branches of the network clustered into
modules were assigned a colour and a numeric value (Fig. 3a and b).
Using the same criteria for module assignment HC and PHC networks
contain 8 and 12 modules, respectively. Constructed networks were
also visualized in Cytoscape, where node colour indicated module
membership (Supplementary Fig. 3).
Jaccard similarity index indicated a high overlap between HC mod-
ule 2 and PHC module 2 (Supplementary Fig. 4). Other modules with
high protein membership overlap (Jaccard index ≥0.1) included HC
module 1 and PHC modules 3 and 7 as well as HC module 3 and PHC
module 1.
Correlation analysis of protein expression proﬁles of post-SE sam-
ples, indicated modules of interest for further analysis. Based on a
threshold of 0.2 of protein signiﬁcance we selected modules 3, 4, 6
and 7 from the HC network and modules 1, 3, 4, 7, 8 and 12 from the
PHC network (Supplementary Fig. 5). Please note that the arbitrary
threshold of 0.2 refers to protein signiﬁcance, whichdescribes the corre-
lation of protein expression proﬁles with samples from animals with a
SE history. Thus, selected modules have a minimum 20% correlation
with the post-SE condition.
To further investigate the link of modules with the post-SE state, we
regressed module eigengenes on SE status. Protein expression proﬁles
of a particular module can be summarized by the ﬁrst principal compo-
nent, also referred to as module eigengene. We evaluated correlation
between module eigengenes and the history of a SE by Spearman's
rank correlation coefﬁcient. According to our deﬁned criteria (p-value
b 0.001 for at least two time points), previously highlighted modules
as well as novel ones were signiﬁcantly associated with SE (Fig. 3c and
d). Modules with negative correlation with the history of a SE included
HC modules 3, 4, 6, 7 and PHC modules 4, 5, 7. These modules have a
large number of proteins that are down-regulated in SE samples. PHC
modules 3 and 8 have positive SE association at all time points, where
proteins are predominantly over-expressed in SE samples. HC module
8 as well as PHC modules 1 and 12 exhibited a mixed (positive and in-
verse) association at different time points.
3.3. Functional enrichment and regulatory proteins
To determine functional enrichment of the modules, each module
was analysedwith IPA. The top 5 enriched pathways for the highlighted
modules are represented in Fig. 4. Signiﬁcantly enriched pathways for
example included Rho family signaling (HC module 3, 4 and PHC mod-
ule 3, 8), HIPPO signaling (HC module 4), 14-3-3 family signaling (HC
module 4), amyloid processing (HC module 6), axonal guidance signal-
ing (HC module 3, 6), chemokine signaling (HC module 7), gluconeo-
genesis (HC module 8), dopamine in cAMP signaling (PHC module 1),
mitochondrial dysfunction (PHC module 3, 7, 12), mTOR signaling
(PHCmodule 5), production of nitric oxide and reactive oxygen species
in macrophages (HC module 7), and leukocyte extravasation signaling
(PHC module 8). Based on the outcome of the pathway enrichment
analysis we also assessed whether modules can be linked with distinct
aspects of epileptogenesis. Some of the modules stand out regarding
an obvious functional association of their top regulated pathways. For
example HC module 4 comprises several signiﬁcantly enriched path-
ways, which are involved in control and regulation of cell death and ap-
optosis as well as protein degradation. Respective pathways include
HIPPO signaling, 14-3-3-mediated signaling, Myc mediated apoptosis
signaling, and the protein ubiquitination pathway. HC modules 3 and
6 are characterized by the regulation of proteins playing a role in cellular
plasticity (3: signaling by Rho family GTPases, RhoGDI signaling, RhoA
signaling, axonal guidance signaling; 6: actin cytoskeleton signaling, ep-
ithelial adherens junction signaling, axonal guidance signaling) or being
linkedwith other neurological diseases (Huntington's disease signaling,
amyloid processing). The list of top 5 regulated pathways of HCmodule
8 comprises pathways, which are involved in carbohydrate and amino
Fig. 2. Classiﬁcation of differentially expressed proteins: Proteins were classiﬁed regarding biological process (a and b) and molecular function (c and d) in the HC (a and c) and
the PHC (b and d).
168 M. Keck et al. / Neurobiology of Disease 105 (2017) 164–178
acid metabolism (gluconeogenesis 1, GDP-mannose biosynthesis, as-
partate degradation II, citrulline biosynthesis, glycogen degradation).
In the PHC module 5 is characterized by enrichment of pathways
linked with the regulation of cell death and apoptosis (EIF2 signaling,
regulation of eIF4 and p70S6K signaling, phagosome maturation,
mTOR signaling). PHC module 8 comprises pathways involved in plas-
ticity and leukocyte transendothelial migration (signaling by Rho family
GTPases, RhoA signaling, actin cytoskeleton signaling, leukocyte extrav-
asation signaling).
Highly connected nodes of the network, often called hubs, serve as
the information ﬂow centers in the small-world, free-scale networks
(Albert et al., 2000). Multiple molecular and brain networks indicated
that hub targeting leads to lethal effect on the functional level (Jeong
et al., 2001; Stam et al., 2007). Thus, hubs can be considered as regula-
tory elements of themodules.Wehighlighted the top 15 connected pro-
teins within SE-associated modules and indicated their relative degree
by the font size (Fig. 4). The lists of top 5 connected proteins permodule
were further checked for signiﬁcantly regulated hub proteins. In the HC
themajority of signiﬁcantly regulated hub proteins proved to be down-
regulated (Table 1). Only selected hippocampal hub proteins exhibited
an upregulation. These included acyl-CoA dehydrogenase, long chain
(HCmodule 4) induced during the latency phase, i.e. ten days following
SE, as well as clusterin (HC module 7) induced at all time points during
epileptogenesis and following epilepsy manifestation (Table 1). A
higher number of hub proteins showed an overexpression in the PHC
(Table 2). The list of respective proteins comprised eukaryotic transla-
tion initiation factor 3 subunit C (PHC module 1; two and ten days
post SE), ribosomal protein L30 (PHC module 4; two and ten days post
SE), and synaptotagmin binding, cytoplasmic RNA interacting protein
(PHC module 4; two and ten days post SE). In PHC module 5 four of
the top 5 hub proteins exhibited an upregulation in the course of
epileptogenesis and epilepsy manifestation: opioid binding protein/
cell adhesion molecule like (ten days post SE), integrin subunit beta 1
(two and ten days and eight weeks post SE), integrin subunit alpha 6
(two and ten days and eight weeks post SE), and neuronal growth reg-
ulator 1 (ten days post SE). All top 5 hub proteins of PHC module 8
proved to be signiﬁcantly induced with one protein regulated ten days
post SE (nicotinamide nucleotide transhydrogenase), one protein
Fig. 3.WGCNA results for the HC and the PHC: Network dendrograms and module assignments are shown in (a and b). Vertical “leaves” of the dendrogram represent genes. The y-axis
represents network distance, which is determined by 1–topological overlap (TO). Values closer to 1 indicate greater dissimilarity of probe expression proﬁles across the samples. Colour
blocks below denote the module assignment determined by Dynamic Hybrid algorithm. The height cut off for dendrogram dissection into modules was determined by Dynamic Hybrid
algorithm. Dendrogram constructed for the HC network (a) with height cut off 0.992 resulted in 8 modules. Dendrogram constructed for the PHC network (b) with height cut off 0.993
resulted in 12modules.Module eigengene correlationwith SE is given in (c and d). HC (c) and PHC (d)modules showed a negative correlationwith SE, if proteinswere under-expressed in
SE samples, and a positive correlation, if proteins were over-expressed in SE samples. Spearman's rank correlation values are indicated on the top with respective Student asymptotic p-
values below.
169M. Keck et al. / Neurobiology of Disease 105 (2017) 164–178
regulated ten days and eight weeks post SE (annexin A3) and the other
hub proteins being regulated at all time points (annexin A2, H2A his-
tone family member Y, and annexin A4).
Hub-disease associationwasqueried inOMIM(Hamosh et al., 2005),
IPA and DisGeNET databases. All signiﬁcantly up-regulated hubs had an
associated OMIM term. DisGeNET indicated a strong association
Fig. 4. Functional enrichment of modules and intramodular hubs: Tables list the top 5 canonical pathways identiﬁed by IPA. Figures present the top 150 protein connections within each
module. The labeled nodes denote the top 15 intramodular hubs in the module. Protein name size is proportional to the relative degree of the node within the respective module. Node
colour reﬂects the previously assigned module membership in the network dendrogram.
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between Alzheimer's disease and clusterin (score = 0.29). Lower
DisGeNET scores of 0.12 were observed between Amyotrophic Lateral
Sclerosis and clusterin as well as opioid binding protein/cell adhesion,
between Schizophrenia and integrin subunit alpha 6, between
Parkinson's Disease and transaldolase 1, and between Spinocerebellar
Ataxia and hypoxia up-regulated 1 (Fig. 5).
The association of hub proteins with neurological diseases is repre-
sented in Supplementary Fig. 6.
We analysed data sets of earlier epilepsy-related proteomics and
transcriptomics studies, testingwhether hub proteins thatwe identiﬁed
have been demonstrated to be regulated in respective studies. The re-
sults are listed in Supplementary Table 2. A differential expression of
some of the hub proteins has been described earlier. For example an in-
duction of clusterin has been reported by Lee et al. (2007) andHansen et
al. (2014).
Additionally, we compared the molecular processes identiﬁed by
our study with available data sets from transcriptomic studies. This
comparison indicated a regulation of similar processes in several stud-
ies. Gorter et al. (2006) detected similar changes and major categories
of processeswith a regulation of apoptosis and cell death aswell as plas-
ticity associated molecular processes. Okamoto et al. (2010) demon-
strated an up-regulation of the expression of genes linked with
extracellular matrix remodelling and cell motility, signaling cascades,
apoptosis or immune response. He et al. (2014) carried out an in-
depth analysis of the dataset generated by Niesen et al. (2013). They re-
ported a regulation of metabolism – associated pathways. In our study
we identiﬁed module 8 in the HC data sets, which was functionally
dominated by pathways involved in cellular metabolism.
In general, it needs to be taken into account that comparison of dif-
ferent data sets faces major limitations related to different study ap-
proaches including time of sampling and different techniques a direct
comparison between studies is biased.When comparing data for differ-
ent brain regions across studies, these are of course often contrasting.
For instance, in a transcriptomic analysis a hippocampal down- regula-
tion of H2A histone family, member Y has been described which
persisted during epileptogenesis (Hansen et al., 2014) We observed an
induction for this protein at all analysed time points in the PHC.
3.4. In-silico result validation
To validate the identiﬁed hubs and functionalmodules, we addition-
ally analysed the proteomic data set provided by Bitsika et al. (2016).
The main differences between our and Bitsika's data set were the
model organism (rat vs. mouse), SE induction (electrical vs. kainic acid
(KA)) and the measured time points (two days, ten days and eight
weeks vs. one, three and 30 days). Despite the great differences be-
tween data sets, the same supporting ﬁndings will indicate that the re-
sults are robust across organisms and SE models. In the following we
refer to our present data sets as HC and PHC.
Brieﬂy, the Bitsika data set underwent the same preprocessing and
network construction steps. Among initial 1715 proteins identiﬁed at
all three time points, 1326 of these proteins overlapped with HC pro-
teins and 1351 with PHC proteins. From initial 1715 proteins identiﬁed
at different time points, we retained only 1045 proteins that were pres-
ent at all time points. Hippocampal data from both studies were com-
pared regarding time course patterns (Supplementary Fig. 7a). The
strongest differentially expressed protein overlaps were identiﬁed for
Bitsika 1 day vs. HC 10 days (14 proteins), Bitsika 3 days vs. HC
10 days (18 proteins), and Bitsika 30 days vs. HC 10 days (41 proteins).
Identiﬁed differentially expressed proteins (Supplementary Fig. 7b) had
the same ratio as in the original publication: lowest number of differen-
tially expressed proteins at day 1 (53), a larger number of differentially
Table 1
Top 5 intramodular hubs for modules in the HC.
Gene symbol Protein Connectivitya p-Valueb Fold changeb p-Valueb Fold changeb p-Valueb Fold changeb
2 days post SE 10 days post SE 8 weeks post SE
Module 3
Wdr7 WD repeat domain 7 1.000 0.048 0.81 0.006 0.68 0.952 0.99
Wdr37 WD repeat domain 37 0.916 0.248 0.87 0.059 0.78 0.907 0.99
Pck2 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) 0.904 0.709 0.95 0.005 0.68 0.254 0.90
Pip5k1c Phosphatidylinositol-4-phosphate 5-kinase type 1 gamma 0.888 0.064 0.82 0.001 0.62 0.329 0.90
Cpne5 Copine 5 0.885 0.025 0.78 0.012 0.67 0.112 0.87
Module 4
Acadl Acyl-CoA dehydrogenase, long chain 1.000 0.022 1.32 0.006 1.51 0.538 1.05
Sec23a Sec23 homolog A, coat complex II component 0.924 0.000 0.37 0.000 0.35 0.833 0.97
Lta4h Leukotriene A4 hydrolase 0.919 0.010 1.41 0.082 1.27 0.291 1.08
Dlg4 Discs large MAGUK scaffold protein 4 0.917 0.045 0.83 0.002 0.66 0.155 0.87
Adap1 ArfGAP with dual PH domains 1 0.858 0.014 0.74 0.023 0.75 0.151 0.85
Module 6
Sbf1 SET binding factor 1 1.000 0.023 0.78 0.018 0.77 0.884 1.04
Wdr47 WD repeat domain 47 0.931 0.013 0.75 0.006 0.63 0.919 1.02
Trio Trio Rho guanine nucleotide exchange factor 0.845 0.001 0.59 0.003 0.51 0.835 1.10
Rasal1 RAS protein activator like 1 (GAP1 like) 0.835 0.027 0.69 0.001 0.59 0.873 0.97
Scai Suppressor of cancer cell invasion 0.813 0.150 0.80 0.032 0.66 0.644 0.93
Module 7
Map2k1 Mitogen activated protein kinase kinase 1 1.000 0.041 0.76 0.004 0.68 0.662 0.95
Clu Clusterin 0.987 0.001 2.86 0.003 5.14 0.037 2.06
Cadps Calcium dependent secretion activator 0.953 0.335 0.92 0.006 0.69 0.242 0.82
Camkk1 Calcium/calmodulin-dependent protein kinase kinase 1 0.882 0.037 0.70 0.009 0.57 0.704 0.95
Pak3 P21 (RAC1) activated kinase 3 0.874 0.598 0.95 0.021 0.69 0.250 0.85
Module 8
Gls Glutaminase 1.000 0.339 1.09 0.026 0.75 0.101 0.87
Got1 Glutamic-oxaloacetic transaminase 1 0.884 0.511 1.06 0.011 0.80 0.347 0.94
Soga3 SOGA family member 3 0.852 0.500 1.07 0.010 0.78 0.751 0.97
Ppp3ca Protein phosphatase 3 catalytic subunit alpha 0.805 0.793 1.03 0.022 0.73 0.306 0.90
Psmd1 Proteasome 26S subunit, non-ATPase 1 0.782 0.256 1.13 0.294 0.91 0.942 1.00
a Proteins with highest connectivity within the module were deﬁned as intramodular hubs.
b Differentially expressed proteins were deﬁned as proteins with fold change ≥1.5 (up-regulated in SE samples) or fold change ≤0.67 (down-regulated in SE samples) and p-values b 0.05.
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expressed proteins at day 3 (73) and the greatest number of differen-
tially expressed proteins at the last time point (250). Spearman's corre-
lation matrix showed a higher correlation between KA-samples and
controls at three days aswell as KA-samples at 30 days (Supplementary
Fig. 7c).
Topological overlap dissimilarity identiﬁed eleven modules in the
Bitsika network (Supplementary Fig. 7d) with size ranging from 48 to
198 proteins. Protein signiﬁcance N0.2 andmodule eigengene trait-cor-
relation (p-value b 0.001) highlighted the Bitsikamodules 3, 4, 5, 10 and
11 (Supplementary Fig. 7e and f). These modules were enriched in mi-
tochondrial dysfunction (module 3 p-value = 7.18e−14, module 10
p-value = 6.92e−07), in melatonin and cancer signaling (module 4
p-value = 6.17e−10, module 11 p-value= 1.3e−05), and in EIF2 sig-
naling (module 5 p-value = 1.05e−06).
Next, we compared if some hub proteins from our data set also ap-
peared as hubs in Bitsika modules. Several hub proteins including bas-
soon (presynaptic cytomatrix protein) (HC 7, Bitsika 10), clusterin (HC
7, Bitsika 4), heat shock protein 4-like (PHC 1, Bitsika 7), myosin XVIIIa
(HC 5, Bitsika 9) and 14–3-3 protein theta (PHC 12, Bitsika 2) exhibited
an overlap between modules from the two studies.
3.5. Principal component analysis (PCA)
The analysis of PCA data was focused on dimension 1 (principal
component 1), which by deﬁnition exhibits the largest variation be-
tween groups under comparison. It is interesting to note that there is
an obvious clustering of the subgroup's HC data along dimension 1
two and ten days but not eight weeks post SE. In contrast, clustering
of PHC data is evident at all three time points (Fig. 6).
Among top 10 proteins that contribute to variability of principal
component 1 (PC1), there are some that exhibit a high fold change
(Tables 3 and 4). In accordance with our aim to identify interesting bio-
marker candidates of epileptogenesis and early epilepsy onset we have
searched these lists for proteins with an upregulation of at least 1.5 fold.
In the early post insult phase (two days post SE) three proteins contrib-
uting to PC1 variability exhibited a strong induction. These included
Table 2
Top 5 intramodular hubs for modules in the PHC.
Gene
symbol
Protein Connectivitya p-Valueb Fold changeb p-Valueb Fold changeb p-Valueb Fold changeb
2 days post SE 10 days post SE 8 weeks post SE
Module 1
Pgk1 Phosphoglycerate kinase 1 1.000 0.066 0.88 0.004 0.76 0.491 0.92
Eif3c Eukaryotic translation initiation factor 3 subunit C 0.984 0.002 2.33 0.002 2.92 0.186 0.83
Psmc1 Proteasome 26S subunit, ATPase 1 0.972 0.011 0.77 0.005 0.74 0.125 1.12
Auh AU RNA binding methylglutaconyl-CoA hydratase 0.952 0.012 1.34 0.008 1.39 0.161 0.84
Hyou1 Hypoxia up-regulated 1 0.948 0.004 0.72 0.004 0.66 0.001 1.52
Module 3
Gmfb Glia maturation factor, beta 1.000 0.029 0.42 0.000 0.24 0.025 0.62
Park7 Parkinsonism associated deglycase 0.896 0.035 0.59 0.000 0.38 0.100 0.85
Dbnl Drebrin-like 0.878 0.091 0.64 0.037 0.56 0.022 0.65
Uchl1 Ubiquitin C-terminal hydrolase L1 0.849 0.420 0.81 0.016 0.48 0.008 0.72
Nsﬂ1c NSFL1 cofactor 0.843 0.125 0.64 0.001 0.39 0.831 1.03
Module 4
Arhgap44 Rho GTPase activating protein 44 1.000 0.001 0.65 0.000 0.63 0.380 0.91
Rpl30 Ribosomal protein L30 0.991 0.000 1.87 0.000 1.88 0.650 0.94
Prkce Protein kinase C, epsilon 0.965 0.001 0.66 0.000 0.65 0.237 0.86
Syncrip Synaptotagmin binding, cytoplasmic RNA interacting protein 0.946 0.002 1.77 0.009 1.90 0.121 1.15
Ube2o Ubiquitin-conjugating enzyme E2O 0.944 0.000 0.53 0.001 0.50 0.011 0.76
Module 5
Opcml Opioid binding protein/cell adhesion molecule-like 1.000 0.176 1.22 0.036 1.58 0.025 1.29
Itgb1 Integrin subunit beta 1 1.000 0.008 1.62 0.000 2.41 0.000 2.16
Itga6 Integrin subunit alpha 6 0.961 0.099 1.64 0.000 3.32 0.000 2.17
Negr1 Neuronal growth regulator 1 0.931 0.159 1.29 0.009 1.73 0.073 1.32
Nefh Neuroﬁlament, heavy polypeptide 0.929 0.075 0.69 0.002 0.35 0.515 0.89
Module 7
Hebp1 Heme binding protein 1 1.000 0.059 0.47 0.001 0.22 0.013 0.42
Prdx5 Peroxiredoxin 5 0.983 0.089 0.71 0.003 0.47 0.208 0.82
Chchd3 Coiled-coil-helix-coiled-coil-helix domain containing 3 0.924 0.261 0.75 0.004 0.48 0.044 0.57
Ndufv2 NADH:ubiquinone oxidoreductase core subunit V2 0.897 0.511 0.76 0.004 0.36 0.217 0.55
Atp5h ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d 0.890 0.930 0.97 0.030 0.53 0.006 0.44
Module 8
Anxa2 Annexin A2 1.000 0.000 3.16 0.000 4.54 0.000 3.11
Anxa3 Annexin A3 0.960 0.060 1.60 0.000 10.38 0.000 2.59
H2afy H2A histone family, member Y 0.953 0.005 1.58 0.000 3.01 0.005 2.03
Nnt Nicotinamide nucleotide transhydrogenase 0.916 0.023 1.27 0.009 1.51 0.022 1.26
Anxa4 Annexin A4 0.882 0.003 1.74 0.000 3.33 0.000 1.93
Module 12
Ywhab 14-3-3 protein beta-subtype 1.000 0.001 0.71 0.001 0.65 0.809 0.98
Prkar1b Protein kinase cAMP-dependent type 1 regulatory subunit beta 0.925 0.001 0.60 0.000 0.50 0.179 1.21
Oxsm 3-oxoacyl-ACP synthase, mitochondrial 0.895 0.001 0.64 0.002 0.60 0.015 1.29
Taldo1 Transaldolase 1 0.888 0.000 1.56 0.001 1.51 0.049 0.84
Ywhag 14-3-3 protein gamma 0.865 0.002 0.73 0.002 0.66 0.808 0.98
a Proteins with highest connectivity within the module were deﬁned as intramodular hubs.
b Differentially expressed proteins were deﬁned as proteins with fold change ≥1.5 (up-regulated in SE samples) or fold change ≤0.67 (down-regulated in SE samples) and p-values b 0.05.
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CD151 molecule, mannose-P-dochilol utilization defect 1 protein and
clusterin. During the latency phase (ten days post SE) ectonucleoside
triphosphate diphosphohydrolase 1 and plexin B2 proved to be up-reg-
ulated among the PC1 top 10 proteins. In the PHC only one PC1 top 10
protein exhibited a signiﬁcant induction ten days post SE. In the chronic
phase following epilepsy manifestation, four proteins of the PC1 top 10
list showed an overexpression: ATP synthase, H+ transporting mito-
chondrial Fo complex, subunit F2; glutathione S-transferase alpha; pro-
teasome subunit beta type 3; purine nucleoside phosphorylase.
3.6. Immunohistochemistry
For validation purposes we selected three proteins for immunohis-
tochemistry based on the results of the network analysis and PCA.
Ten days following SE an increased expression of eukaryotic transla-
tion initiation factor 3 subunit C was evident in the PHC of animals with
SE. The difference was most pronounced in the amygdalopiriform tran-
sition. Animals with SE exhibited small immunopositive cells in this re-
gion that were not present in control animals (Supplementary Fig. 8a
and b). The immunopositive area proved to be increased by 1.5-fold
(Supplementary Fig. 8c: two-sample t(8) = 5.011, p = 0.001) in ani-
mals following SE (2.496 ± 0.097 n = 5) as compared to control ani-
mals (1.628 ± 0.144 n = 5).
Ten days following SE, we conﬁrmed an increase of annexin A3 ex-
pression in the PHC by immunohistochemistry. All animals with SE
exhibited amarked difference in cell morphology in the piriform cortex,
particularly in layer II (pyramidal layer). Swollen immunopositive cells
that appeared densely packed were observed in animals following SE,
but not in control animals (Supplementary Fig. 8d and e). Despite the pro-
nounced variability among the SE animals, a signiﬁcant 2.2-fold change in
annexin A3 positive area (Supplementary Fig. 8f: two-Welch t(6) =
2.806, p = 0.0309) was demonstrated when comparing animals with
SE (0.229 ± 0.044 n = 7) and control animals (0.104 ± 0.010 n = 6).
As a consequence of SE an increased expression of clusterinwas con-
ﬁrmed in the HC. Two days following SE a trend towards an increased
clusterin expression was evident in the CA1 stratum lacunosum
moleculare of the dorsal HC (Supplementary Fig. 8g–i: two-sample
t(12) = 1.861, p = 0.087, SE 0.049 ± 0.004 n = 7, control 0.039 ±
0.004 n = 7).
In the ventral HC (Supplementary Fig. 8j and k), clusterinwas signif-
icantly upregulated in the CA3 radiatum and lacunosum moleculare
layers (Supplementary Fig. 8l: two-sample t(9) = 2.887, p = 0.0180).
Animals with SE (0.055 ± 0.005 n = 6) displayed a 1.7-fold
increase in the area labeled for clusterin as compared to control animals
(0.034 ± 0.005 n = 5).
4. Discussion
To our knowledge, this study presents the ﬁrst comprehensive
WGCNA-based systems biology analysis, which provides an in-depth
Fig. 5. Up-regulated hubs association with diseases in DisGeNET database: For visualization purpose, we included only associations with DisGeNET score above 0.1.
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characterization of the epileptogenesis-associated proteomic network
alterations. A broad functional annotation analysis revealed a pro-
nounced regulation of several functional groups of proteins. Both, in
the HC and PHC the most prominent molecular alterations in the re-
spective groups were evident during the latency phase, i.e. ten days fol-
lowing the epileptogenic brain insult. This time course seems to reﬂect
the alterations at the cellular and network level, which of course require
a high intensity ofmolecular processes. Thus, it is not surprising that the
groups exhibiting the most pronounced regulation including several
protein groups, which play a key role in synaptic and cellular plasticity
and network reorganization.
The time course pattern of the regulation of functional protein
groups points to another interesting aspect. There is an ongoing discus-
sion to what extent pathophysiological mechanisms during
epileptogenesis overlapwith those in the early phase following epilepsy
manifestation and progression phases (Dudek and Staley, 2011). Our
ﬁndings indicate that some of the molecular pathological processes ex-
tend into the chronic phase with spontaneous recurrent seizures. How-
ever, the degree of their regulation is reduced to lower levels with a
smaller number of proteins being regulated per functional group.
Systems biology approaches and network analyses of omics-data
sets can render an important information basis for network pharmacol-
ogy approaches with multi-targeting strategies or targeting of key tran-
scription factors (Margineanu, 2016; Benson, 2015; Haanstra and
Bakker, 2015). Löscher et al. (2013) have emphasized that there is an
urgent need in the epileptology ﬁeld for a gain-in-knowledge rendering
rational design of multi-targeting approaches and drug cocktails possi-
ble. In line with these concepts we now applied a WGCNA resulting in
the identiﬁcation of several modules of interconnected protein groups,
which reﬂect distinctmolecular aspects of epileptogenesis in the electri-
cal post-SE model in rats. In order to assess the robustness of the ﬁnd-
ings we included another data set recently published by (Bitsika et al.,
2016) from a chemical mouse post-SE model in a direct comparative
analysis.
The functional association of signiﬁcantly enriched pathways char-
acterizing the identiﬁed modules points to key pathophysiological
mechanisms. It is awell-known fact that epileptogenic brain insults trig-
ger neuronal damage and loss (Pitkänen et al., 2002). HC module 4
proved to be characterized by the regulation of molecular signaling
pathways that are critically involved in the regulation of cell death
and apoptosis. Whereas altered 14–3-3 signaling has previously been
discussed in the context of temporal lobe epilepsy (Schindler et al.,
2006), there has been only limited or no information available about
the role of Mycmediated apoptosis signaling, HIPPO signaling, and pro-
tein ubiquitination during epileptogenesis. HIPPO signaling is known to
play a crucial role in the regulation of cell proliferation and apoptosis
(Cairns et al., 2017) as well as in tumorigenesis (Zhang et al., 2016). In
addition, a link has been described between HIPPO signaling and 14-
3-3 proteins (Ren et al., 2010).
The involvement of further pathways was evident in PHCmodule 5.
Among these, mTOR signaling was repeatedly described to bemodulat-
ed during epileptogenesis and in the epileptic brain (Vezzani, 2012;
Fig. 6. Principal Component Analysis (PCA): PCAof control (Ctrl; dots) and SE animals (triangles) performed for each time point (two days, ten days and eightweeks post SE) in theHC and
the PHCwith all identiﬁed proteins at the speciﬁc time point as input. (a) HC two days post SE, (b) HC ten days post SE, (c) HC eight weeks post SE, (d) PHC two days post SE, (e) PHC ten
days post SE, and (f) PHC eight weeks post SE.
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Galanopoulou et al., 2012). In apparent contrast, there has been a lack of
robust information about epileptogenesis- or epilepsy-associated regu-
lation of signaling pathways linkedwith eukaryotic initiation factor and
ribosomal protein S6 kinase beta-1 signaling. These pathways are asso-
ciated with protein synthesis and macroautophagy and a role of these
pathways has been discussed in the context of Parkinson's disease
(Dijkstra et al., 2015). Respective pathways might comprise interesting
target candidates for neuroprotective approaches.
Cellular plasticity constitutes one of the hallmarks of the develop-
ment of temporal lobe epilepsy following an initial brain insult
(Jessberger and Parent, 2015). Two of the HC modules (module 3 and
6) and one of the PHC modules (module 8) stood out with a regulation
of pathways linkedwith cytoskeletal dynamics, cell-cell interaction, and
axonal guidance. The identiﬁcation of these pathways provides impor-
tant molecular information for future development of innovative ap-
proaches interfering with the generation of a hyperexcitable cellular
network. In the PHC, proteins associated with leukocyte extravasation
signaling exhibited an intense regulation. Recently, we have already
discussed respective molecular alterations and their implications in de-
tail (Walker et al., 2016). In this previous publication, we have complet-
ed a bioinformatics analysis focused on inﬂammation and immunity-
associated pathways. Despite the fact that some of the respective path-
ways were also key components of those network modules, which
proved to be regulated following SE, the number of hub proteins and
regulated module pathways linked with inﬂammation is relatively
low. This might be related to a role of inﬂammation-associated proteins
as crucial effector proteins rather than key regulatory proteins.
Moreover, assessment of regulated pathways characterizing HC
module 6 pointed to a molecular overlap with pathophysiological
mechanisms of other neurological diseases. The comparison of the neu-
robiology of Alzheimer's disease and epilepsy has already been a focus
of experimental and clinical studies (Noebels, 2011; Chin and
Scharfman, 2013). In contrast, the mechanistic link between
Huntington's disease and epilepsy suggested by our ﬁndings needs to
be further explored.
In general, it is of interest that several hub proteins of differentmod-
ules have already been linkedwith various neurological and psychiatric
diseases (Fig. 5). Among these hub proteins annexin A2, clusterin, and
integrin subunit beta 1 are standing out exhibiting a link with multiple
diseases.
The regulation of HC module 8 pathways linked with carbohydrate
and amino acid metabolism might reﬂect a general metabolic dysfunc-
tion. Reid et al. (2014) have previously discussed that the modulation
of metabolic pathways can affect seizure susceptibility. Taking this dis-
cussion into account, the comprehensive metabolic alterations evident
from our data sets might actually contribute to epileptogenesis. In addi-
tion, PHCmodules 3 and 7 comprised pathways related tomitochondri-
al function or to mitochondrial dysfunction. It is known that alterations
in cell respiration and in the generation of reactive oxygen species can
affect epileptogenesis (Rowley et al., 2015). Thus, this ﬁnding is in line
with the already discussed association betweenmitochondrial dysfunc-
tion and epilepsy (Folbergrova and Kunz, 2012).
Protein interaction networks are characterized by a small number of
highly connected protein nodes referred to as hub proteins (He and
Table 3





2 days post SE
Cd151 CD151 molecule (Raph blood group) 0.016 1.89
Gprc5b G protein-coupled receptor, class C, group 5,
member B
0.052 1.61
Slc25a4 Solute carrier family 25 member 4 0.074 1.23
Mpdu1 Mannose-P-dolichol utilization defect 1 0.000 1.73
Slc25a3 Solute carrier family 25 member 3 0.340 1.12
Sfxn3 Sideroﬂexin 3 0.099 1.17
Lamp1 Lysosomal-associated membrane protein 1 0.085 1.36
Clu Clusterin 0.001 2.86
Acadvl Acyl-CoA dehydrogenase, very long chain 0.069 1.53
Mpc2 Mitochondrial pyruvate carrier 2 0.877 1.01
10 days post SE
Itgb1 Integrin subunit beta 1 0.054 2.39
Itga6 Integrin subunit alpha 6 0.054 2.75
Nnt Nicotinamide nucleotide transhydrogenase 0.831 1.02
Hspc159 Galectin-like 0.044 0.51
Entpd1 Ectonucleoside triphosphate diphosphohydrolase 1 0.029 2.70
Cd48 CD48 molecule 0.111 6.15
Bsn Bassoon (presynaptic cytomatrix protein) 0.026 0.53
Slc5a3 Solute carrier family 5 member 3 0.054 2.28
Hebp1 Heme binding protein 1 0.051 0.49
Plxnb2 Plexin B2 0.021 2.44
8 weeks post SE
Myh9 Myosin, heavy chain 9, non-muscle 0.518 1.32
Plec Plectin 0.510 1.28
Tmod1 Tropomodulin 1 0.351 1.26
Ctnnd2 Catenin delta 2 0.481 1.22
Ablim2 Actin binding LIM protein family, member 2 0.563 1.23
Pea15 Phosphoprotein enriched in astrocytes 15 0.375 0.78
Myh10 Myosin, heavy chain 10, non-muscle 0.550 1.30
Dnaja1 DnaJ heat shock protein family (Hsp40) member
A1;
0.628 1.14
Wdr48 WD repeat domain 48 0.375 1.15
Myo18a Myosin XVIIIa 0.615 1.12
a Differentially expressed proteins were deﬁned as proteins with fold change ≥1.5
(up-regulated in SE samples) or fold change ≤0.67 (down-regulated in SE samples)
and p-values b 0.05.
Table 4





2 days post SE
Cyp46a1 Cytochrome P450, family 46, subfamily a,
polypeptide 1
0.000 0.44
Abr Active BCR-related 0.001 0.69
Inpp1 Inositol polyphosphate-1-phosphatase 0.000 0.60
Brsk2 BR serine/threonine kinase 2 0.000 0.59
Ywhah 14-3-3 protein eta 0.001 0.75
Wars Tryptophanyl-tRNA synthetase 0.003 0.78
Strn3 Striatin 3 0.001 0.58
Oxsm 3-oxoacyl-ACP synthase, mitochondrial 0.001 0.64
Esd Esterase D 0.004 0.80
Actbl2 Actin, beta-like 2 0.000 0.50
10 days post SE
Ywhab 14-3-3 protein beta-subtype 0.001 0.65
Hspa4l Heat shock protein 4-like 0.003 0.78
Strn4 Striatin 4 0.000 0.47
Ywhae 14-3-3 epsilon 0.003 0.75
Anxa3 Annexin A3 0.000 10.38
Pgls 6-Phosphogluconolactonase 0.000 0.51
Park7 Parkinsonism associated deglycase 0.000 0.38
Aco1 Aconitase 1 0.001 0.69
Esd Esterase D 0.002 0.75
Ywhaq 14-3-3 protein theta 0.001 0.66
8 weeks post SE
Agk Acylglycerol kinase 0.148 1.15
Got2 Glutamic-oxaloacetic transaminase 2 0.243 1.12
Ogdh Oxoglutarate dehydrogenase 0.143 1.19
Atp5j2 ATP synthase, H+ transporting, mitochondrial Fo
complex, subunit F2
0.002 1.71
Atp5a1 ATP synthase, H+ transporting, mitochondrial F1
complex, alpha subunit 1, cardiac muscle
0.240 1.10
Gsta1 Glutathione S-transferase alpha 1 0.011 1.62
Psmb3 Proteasome subunit beta 3 0.005 1.73
Trap1 TNF receptor-associated protein 1 0.084 1.17
Pnp Purine nucleoside phosphorylase 0.027 1.55
Ddb1 Damage-speciﬁc DNA binding protein 1 0.060 1.24
a Differentially expressed proteins were deﬁned as proteins with fold change ≥1.5
(up-regulated in SE samples) or fold change ≤0.67 (down-regulated in SE samples)
and p-values b 0.05.
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Zhang, 2006). Themajority of the signiﬁcantly regulated top 5 hub pro-
teins that we identiﬁed in our data set can be assigned to functional
pathways discussed above. However, some hub proteins stand out
from a functional point of view. These include synaptotagmin serving
as a calcium sensor function thereby regulating neurotransmitter re-
lease (Jackman et al., 2016); H2A histone family member Y, a nuclear
protein inﬂuencing nucleosome structure and regulating transcription
(Hu et al., 2011) as well as different annexins playing a role in pro-in-
ﬂammatory arachidonic acid signaling (Creutz et al., 2012). Several of
these proteins including eukaryotic translation initiation factor 3 sub-
unit C, H2A histone family member Y, hypoxia up-regulated 1, and
transaldolase 1 have to our knowledge not been discussed in the con-
text of epileptogenesis before.
Some of the intramodular hub proteins were also identiﬁed by PCA,
such as, for instance, annexin A3. Junker et al. (2007) discussed a role for
annexin A3 in apoptotic and phagocytotic processes in the brain. Thus,
the detected upregulation in the latency phase, which was conﬁrmed
by immunohistochemistry, might be related to insult-triggered cell
death.
On the ﬁrst glimpse, hub proteins might serve as interesting target
candidates based on their key switch function in the disease-associated
protein-protein network. However, it needs to be considered that dele-
tion of hub proteins has a higher probability to be lethal than deletion of
a non-hub protein (He and Zhang, 2006). Thus, pharmacological
targeting of hub proteins has a high potential for severe adverse effects
and tolerability issues. Nevertheless, knowledge about hub proteins,
their interactions and associated loops provides valuable information
allowing integration of network biology in the design of module-
based targeting approaches (Hopkins, 2008; Wang et al., 2012).
For comparative validation of the ﬁndings we have subjected a re-
cently published data set to WGCNA analysis. The comparison revealed
a partial overlap in enriched pathways characterizing identiﬁed mod-
ules and in hub proteins. These data provide ﬁrst evidence for the ro-
bustness of our ﬁndings. The outcome of the comparison needs to
consider that there are some similarities between themodels regarding
predictive validity. Both, the electrical and the chemical post-SE model
have been described as models with difﬁcult-to-treat or drug-resistant
seizures (Löscher, 2011). On the other hand, there are huge differences
in the experimental design of both studies and characteristics of the
models, including the use of rats vs. mice, application of an electrical
vs. chemical stimulus, requirement of electrode implantation vs. local
injection, development of generalized tonic-clonic seizures vs. a mix-
ture of non-convulsive electrographic seizures and behavioral convul-
sive seizures, and a week-long latency period vs. immediate
epileptogenesis.
It is interesting to note that we observed an overlap in the network
data despite these contrasting characteristics of the constructive and
face validity of the models. This fact points to shared molecular patho-
physiological mechanisms between the models, which might further
conﬁrm a comparable predictability regarding target and biomarker
identiﬁcation.
During the early post-insult phase and the latency phase PCA analy-
sis of data from both brain regions revealed an obvious clustering also
pointing to proteins that best distinguish between groups. The top pro-
tein lists contributing to dimension 1 might suggest biomarker candi-
dates, which can serve as early molecular predictors of epileptogenesis
following a brain insult. As mentioned in the introduction respective
biomarkersmight render a basis formolecular imaging approaches suit-
able for the identiﬁcation of subgroups of patients at risk to develop ep-
ilepsy and for efﬁcacy testing when evaluating anti-epileptogenic
approaches. Thereby, proteins exhibiting a prominent upregulation
should provide the most interesting candidates. Proteins, which as
CD151 molecule proved to be overexpressed two days following SE,
might be the most promising biomarkers for early risk assessment. It
would be of particular interest to further study the regulation of
CD151molecule in more detail considering that CD151molecule serves
as a target for valproate and lithium in bipolar disorders (Hua et al.,
2001) and that it might contribute to the regulation of blood-brain bar-
rier tightness (Zhang et al., 2011). Proteins being up-regulated ten days
following SE such as plexin B2 might provide a basis for follow-up and
efﬁcacy testing of intervention strategies. In contrast, proteins
exhibiting a signiﬁcant induction following onset of epilepsy might
serve as a valuable basis for early diagnosis of epilepsy manifestation.
Based on our analysis, molecular alterations in the PHC rather than
those in the HC can provide a basis for respective epilepsy biomarkers.
As a major limitation of any molecular study with brain tissue sam-
pling at early time points following an epileptogenic brain insult, we
could only base our study design on the choice of a model in which an-
imals reliably develop spontaneous seizures. It needs to be taken into
account that invasive sampling does not allow to subsequently obtain
information about the outcome regarding epilepsy development. The
current study design of course does not allow toﬁnally concludewheth-
er a selected molecular alteration is associated with epileptogenesis or
whether it merely reﬂects a consequence of the initial brain insult.
Thus, it will be of utmost interest to assess whether biomarker candi-
dates reliably predict epileptogenesis in a model with subgroups of an-
imals with or without development of spontaneous recurrent seizures.
This however, will only be feasible with a non-invasive assessment of
the biomarker candidates e.g. by molecular imaging. The situation
would of course be different with peripheral biomarkers from plasma
or peripheral tissue aswell aswith cerebrospinal ﬂuid sampling. Assess-
ment of proteome alterations in respective samples should be further
addressed in future studies. However, it needs to be taken into account
that a sufﬁcient number of proteins is necessary for a network analysis,
whichwe have completed in the present study. The low number of pro-
teins in CSF samples would therefore hamper this speciﬁc type of bioin-
formatics analysis.
Considering the outcome of the bioinformatics analysis it needs to be
taken into account that databases used are based on amixture of in vivo
and in vitro data. With the currently available tools it is not possible to
avoid a putative bias related to the fact that data obtained from an ani-
mal model are analysed based on these databases.
Moreover, data sets require validation by a focused analysis of se-
lected proteins. Immunohistochemical analysis can thereby also pro-
vide additional information about the subregion speciﬁc and cellular
distribution of differentially expressed proteins. In the present study,
we conﬁrmed an up-regulation of three selected proteins. These includ-
ed annexin A3, which has already been discussed above, the chaperone
protein clusterin, and eukaryotic translation initiation factor 3 subunit C.
To our knowledge a regulation of the latter protein has not been
discussed previously in the context of epileptogenesis. Eukaryotic trans-
lation initiation factor 3 subunit C, serves an essential function during
the initiation of protein synthesis (Emmanuel et al., 2013). Silencing of
its function can inhibit cell proliferation and promote apoptosis (Hao
et al., 2015). It might be of interest to further study the role of this pro-
tein during epileptogenesis in more detail in future studies.
In conclusion, theﬁrst systems level analysis of proteome alterations
during the course of epileptogenesis identiﬁed several modules of high-
ly connected proteins in the HC and PHC. Characterization of the mod-
ules did not only further validate the data, but also revealed regulation
of molecular processes not described previously in the context of epi-
lepsy development. The data sets also provide valuable information
about temporal patterns required for the development of preventive
strategies.
In addition, PCA analysis suggests candidate biomarkers, which
might inform the design of novel molecular imaging approaches aiming
to predict epileptogenesis duringdifferent phases or to conﬁrmepilepsy
manifestation.
It is emphasized that the study design and the ﬁndings do not yet
allow to distinguish between proteins that are undoubtedly linked
with epileptogenesis and do not only reﬂect a molecular consequence
of SE. Further studies with sequential molecular imaging in models
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with subgroups with and without epilepsy development, will be crucial
to provide relevant information about selected candidates. Moreover,
application of network analysis to other models of epileptogenesis
with different types of epileptogenic insults including models of trau-
matic brain injury or ischemia will provide data for comparison
allowing the identiﬁcation of key epileptogenesis proteins.
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